Jeff Parr

FCPA

Founder and CEO

Bowen’s FX Therapeutics

Vice Chairman

Clairvest Group Inc.

Jeff Parr is a proud grandfather to Bowen, who was diagnosed with Fragile X Syndrome in 2023. Motivated by his family’s journey, Jeff founded Bowen’s FX Therapeutics, a venture dedicated to accelerating the development of curative therapies for Fragile X, with an initial focus on protein replacement therapy.

Drawing on more than 35 years of experience in private equity and financial leadership, Jeff brings a unique perspective on how strategic investment and innovation can drive progress in rare disease research. He is Vice Chairman at Clairvest Group Inc. (TSX:CVG), Founder and CEO of Bowen’s FX Therapeutics, and serves on the Investment Committee at the University of Western Ontario, where he earned both his BA and Doctor of Laws.

Jeff’s professional career has centred on supporting entrepreneurs in the growth and development of their companies. Today, he applies that same expertise and the power of community collaboration to advance life-changing solutions for those affected by Fragile X.